Company Filing History:
3 out of 576 
1 out of 159 Years Active: 2018-2025
Title: Innovator in Viral Therapeutics: Shigeki Miyake-Stoner
Introduction
Shigeki Miyake-Stoner is an accomplished inventor located in La Jolla, California. He holds two patents, contributing significantly to the field of viral therapeutics, particularly in the application of adenovirus-based treatments for proliferative disorders.
Latest Patents
Miyake-Stoner's latest inventions include:
1. **Oncolytic Adenovirus Compositions** - This patent describes an adenovirus engineered to include an E1A polypeptide with various modifications, along with an E4orf6/7 polypeptide comprising additional modifications. The invention encompasses compositions and kits that utilize these modified adenoviruses, with a focus on treating proliferative disorders by administering the described adenovirus.
2. **Selective Cell Targeting Using Adenovirus and Chemical Dimers** - This patent presents innovative compositions and methodologies for retargeting adenovirus to specific cells using chemical dimers. It features a recombinant adenovirus that incorporates a nucleic acid with both a capsid-dimerizing agent binder conjugate and a ligand-dimerizing agent binder conjugate.
Career Highlights
Shigeki Miyake-Stoner is associated with the Salk Institute for Biological Studies, where he contributes his expertise in the development of viral therapies. His efforts have the potential to significantly impact the treatment landscape for cancer and other proliferative disorders.
Collaborations
Throughout his career, Miyake-Stoner has collaborated with notable researchers, including Clodagh O'Shea and Colin Powers. These collaborations have fostered innovative approaches to adenoviral therapies and enhance the potential of his inventions in clinical applications.
Conclusion
With his pioneering work in adenoviral technology, Shigeki Miyake-Stoner stands out as a key inventor driving forward the development of innovative therapeutic solutions. His patents reflect a commitment to addressing critical health challenges and improving treatment outcomes for patients affected by proliferative disorders.